

## WEST Search History

DATE: Thursday, August 31, 2006

<b>Hide?</b>	<b>Set Name</b>	<b>Query</b>	<b>Hit Count</b>
	<i>DB=PGPB,USPT,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L5	L4 and synthetic	17
<input type="checkbox"/>	L4	L3 and carrier adj protein	18
<input type="checkbox"/>	L3	L2 and conjugated	57
<input type="checkbox"/>	L2	L1 and solid adj phase	80
<input type="checkbox"/>	L1	424/228.1.ICLS.	141

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1648BQL

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006  
NEWS 4 APR 04 STN AnaVist \$500 visualization usage credit offered  
NEWS 5 MAY 10 CA/Capplus enhanced with 1900-1906 U.S. patent records  
NEWS 6 MAY 11 KOREAPAT updates resume  
NEWS 7 MAY 19 Derwent World Patents Index to be reloaded and enhanced  
NEWS 8 MAY 30 IPC 8 Rolled-up Core codes added to CA/Capplus and  
USPATFULL/USPAT2  
NEWS 9 MAY 30 The F-Term thesaurus is now available in CA/Capplus  
NEWS 10 JUN 02 The first reclassification of IPC codes now complete in  
INPADOC  
NEWS 11 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and  
and display fields  
NEWS 12 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL  
NEWS 13 JUL 11 CHEMSAFE reloaded and enhanced  
NEWS 14 JUL 14 FSTA enhanced with Japanese patents  
NEWS 15 JUL 19 Coverage of Research Disclosure reinstated in DWPI  
NEWS 16 AUG 09 INSPEC enhanced with 1898-1968 archive  
NEWS 17 AUG 28 ADISCTI Reloaded and Enhanced  
NEWS 18 AUG 30 CA(SM)/Capplus(SM) Austrian patent law changes  
  
NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 08:23:56 ON 31 AUG 2006

=> file caplus biosis  
COST IN U.S. DOLLARS

SINCE FILE TOTAL  
ENTRY SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'CAPLUS' ENTERED AT 08:24:12 ON 31 AUG 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 08:24:12 ON 31 AUG 2006  
Copyright (c) 2006 The Thomson Corporation

=> HCV (s) conjugat3  
75% OF LIMIT FOR TOTAL ANSWERS REACHED  
L1 9357874 3

=> solid (s) phase  
L2 222835 SOLID (S) PHASE

=> carrier (w) protein  
L3 14905 CARRIER (W) PROTEIN

=> L1 and l3  
L4 4345 L1 AND L3

=> combinantion  
L5 11 COMBINANTION

=> L4 and L2  
L6 85 L4 AND L2

=> core and L6  
L7 0 CORE AND L6

=> Core (w) antigen  
L8 4778 CORE (W) ANTIGEN

=> L8 and L6  
L9 0 L8 AND L6

=> L8 and L1  
L10 1207 L8 AND L1

=> sensitiz3  
SYSTEM LIMITS EXCEEDED - SEARCH ENDED  
The search profile you entered was too complex or gave too many  
answers. Simplify or subdivide the query and try again. If you have  
exceeded the answer limit, enter DELETE HISTORY at an arrow prompt  
(=>) to remove all previous answers sets and begin at L1. Use the  
SAVE command to store any important profiles or answer sets before  
using DELETE HISTORY.

=> D history

(FILE 'HOME' ENTERED AT 08:23:56 ON 31 AUG 2006)

FILE 'CAPLUS, BIOSIS' ENTERED AT 08:24:12 ON 31 AUG 2006  
L1 9357874 3  
L2 222835 SOLID (S) PHASE  
L3 14905 CARRIER (W) PROTEIN  
L4 4345 L1 AND L3  
L5 11 COMBINANTION  
L6 85 L4 AND L2  
L7 0 CORE AND L6  
L8 4778 CORE (W) ANTIGEN

L9                    0 L8 AND L6  
L10                  1207 L8 AND L1

=> NS3 and L10  
L11                  59 NS3 AND L10

=> NS5 and L11  
L12                  33 NS5 AND L11

=> conjugated and L12  
L13                  0 CONJUGATED AND L12

=> synthetic and L12  
L14                  5 SYNTHETIC AND L12

=> D L14 IBIB ABS 1-5

L14 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:            2004:287791 CAPLUS

DOCUMENT NUMBER:            140:320023

TITLE:                        DNA vaccine comprising plasmids encoding core-E1-E2,  
NS3-NS4 and NS5 genes for enhancing  
protective immunity to hepatitis C virus

INVENTOR(S):                Sung, Young Chul; Youn, Jin-Won; Yang, Se-Hwan; Park,  
Su-Hyung; Lee, Chang Geun

PATENT ASSIGNEE(S):        Genexine Inc., S. Korea; Postech Foundation; Dong-A  
Pharm. Co., Ltd.; Daewoong Co., Ltd.; Posco

SOURCE:                     PCT Int. Appl., 165 pp.

CODEN: PIXXD2

DOCUMENT TYPE:              Patent

LANGUAGE:                    English

FAMILY ACC. NUM. COUNT:    1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004028563	A1	20040408	WO 2003-KR1951	20030924
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
KR 2004027247	A	20040401	KR 2002-68496	20021106
AU 2003263653	A1	20040419	AU 2003-263653	20030924
US 2005287117	A1	20051229	US 2005-528644	20050318
PRIORITY APPLN. INFO.:			KR 2002-58712	A 20020927
			KR 2002-68496	A 20021106
			WO 2003-KR1951	W 20030924

AB The present invention relates to a vaccine enhancing the protective immunity to Hepatitis C virus using plasmid DNA recombinant adenovirus, more particularly to a vaccine consisting of  $\Delta$  core-E1-E2 expressing DNA vaccine, nonstructural protein NS3 and NS4 expressing DNA vaccine, nonstructural protein NS5 expressing DNA vaccine and recombinant adenovirus vaccine, and method for administration of the vaccine by priming with the DNA vaccines described above and boosting with the recombinant adenovirus vaccine thereby enhancing the protective immunity to Hepatitis C virus.

REFERENCE COUNT:            4            THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

L14 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:633162 CAPLUS  
 DOCUMENT NUMBER: 139:178676  
 TITLE: Methods for the simultaneous detection of hcv antigens and hcv antibodies  
 INVENTOR(S): Shah, Dinesh O.; Dawson, George J.; Muerhoff, A. Scott; Jiang, Lily; Gutierrez, Robin A.; Leary, Thomas P.; Desai, Suresh; Stewart, James L.  
 PATENT ASSIGNEE(S): Abbott Laboratories, USA  
 SOURCE: U.S. Pat. Appl. Publ., 63 pp., Cont.-in-part of U.S. Ser. No. 891,983.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003152948	A1	20030814	US 2002-173480	20020617
US 6727092	B2	20040427		
US 2003108858	A1	20030612	US 2001-891983	20010626
CA 2450710	AA	20030109	CA 2002-2450710	20020624
WO 2003002749	A2	20030109	WO 2002-US19958	20020624
WO 2003002749	A3	20030710		
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1412538	A2	20040428	EP 2002-746647	20020624
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2005518186	T2	20050623	JP 2003-509110	20020624
US 2004185436	A1	20040923	US 2004-753910	20040107
US 6855809	B2	20050215		
PRIORITY APPLN. INFO.:			US 2001-891983	A2 20010626
			US 2002-173480	A 20020617
			WO 2002-US19958	W 20020624
AB The subject invention relates to methods for the simultaneous detection of Hepatitis C Virus (HCV) antigens as well as antibodies produced in response to HCV antigens. Furthermore, the subject invention allows one to detect antigens in the early, acute stage of infection, even prior to the development of antibodies, thereby allowing for early detection of infected blood and blood products, thus improving the safety of the blood supply. The method allows the detection of the antigen or the antibody, or both, in a single assay. Antigens are detected with immobilized antibodies and antibodies are detected with immobilized antigens. After incubating the immobilized agents with a test sample, they are then incubated with labeled antibodies. Bound antigen is detected with an antibody to the antigen. Bound antibody is detected with a mouse monoclonal antibody to a human antibody, typically IgG.				

L14 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:124651 CAPLUS  
 DOCUMENT NUMBER: 135:209508  
 TITLE: Diagnostic potential of an enzyme immunoassay system for evaluation of the spectrum of antibodies to hepatitis C structural and nonstructural antigens  
 AUTHOR(S): Pimenov, V. K.; Afanas'ev, A. Yu.; Kolobov, A. A.; Zubov, S. V.; Dobrotina, N. A.; Novikov, V. V.  
 CORPORATE SOURCE: Nizhegorod. Gos. Univ. im. N. I. Lobachevskogo, Nizhniy Novgorod, Russia

SOURCE: Voprosy Virusologii (2000), 45(6), 44-47  
 CODEN: VVIRAT; ISSN: 0507-4088  
 PUBLISHER: Meditsina  
 DOCUMENT TYPE: Journal  
 LANGUAGE: Russian

AB A new enzyme immunoassay EIA-HCV-Spectra test system constructed on the base of recombinant proteins and synthetic peptides allows sep. detection of antibodies to E1/E2, core, NS3, NS4, and NS5 antigens of hepatitis C virus (HCV). The system is highly specific and more sensitive than the test systems used in screening studies, which allows its use as a final test for antiHCV antibodies. Antibodies to various HCV antigens were analyzed using this test system in patients with acute and chronic hepatitis C and asymptomatic donors with antiHCV. In acute hepatitis C during the first-second week after clin. attis C and asymptomatic donors with antiHCV. In acute hepatitis C during the first and second week after clin. manifestation, antibodies to nonstructural virus proteins are detected 3-4 times less often than in chronic hepatitis C. Acute hepatitis C is characterized by the presence of antibodies only to core antigen (66%). In chronic condition combinations of antibodies to structural and nonstructural HCV antigens predominate: core + NS4, core + NS3 + NS4, core + NS3 + NS5, core + NS4 + NS5, and core + NS3 + NS4 + NS5. In asymptomatic donors with antiHCV and in patients with chronic hepatitis C the spectra of antibodies were similar in 45.7% cases.

L14 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:54036 CAPLUS  
 DOCUMENT NUMBER: 126:73782

TITLE: Unprocessed core-envelope fusion protein and nonstructural protein for the diagnosis of and vaccination against hepatitis C virus  
 INVENTOR(S): Liao, Jaw-Ching; Wang, Cheng-Nan  
 PATENT ASSIGNEE(S): Bionova Corporation, USA; Liao, Jaw-Ching; Wang, Cheng-Nan

SOURCE: PCT Int. Appl., 73 pp.  
 CODEN: PIXXD2

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9637606	A1	19961128	WO 1996-US7378	19960522
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
ZA 9604094	A	19961203	ZA 1996-4094	19960522
AU 9659243	A1	19961211	AU 1996-59243	19960522
PRIORITY APPLN. INFO.:			US 1995-447276	A 19950522
			WO 1996-US7378	W 19960522

AB The unprocessed core protein region initially translated from the genome of hepatitis C virus (HCV) contains epitopic configurations that are not retained in the processed proteins. In particular, the core protein loses an epitopic configuration upon processing at the cleavage site between the genomic region (e.g., gene) encoding the core protein and the genomic region encoding the adjacent envelope region. The unprocessed epitopic configuration of the core region provides an improved ability to detect the presence of HCV, or antibodies to HCV, in a sample, including an

unpurified sample or a sample of very small volume (which can be particularly helpful when testing a sample from an infant or other person having very little blood (or other suitable material) available for testing). Combining the unprocessed core region with a nonstructural protein (such as an NS5 or an NS3-NS4 fusion) results in a synergistic effect that greatly enhances the already improved sensitivity and specificity provided by the unprocessed core region. The unprocessed epitopic configuration of the core region also provides an improved ability to induce an immune response upon administration of the core region into an animal. Recombinant methods are described for the preparation of a cloned DNA mol. (EN-80-2) derived from the HCV core and envelope regions and for a clone (EN-80-1) encoding the NS5 nonstructural protein.

L14 ANSWER 5 OF 5 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
ACCESSION NUMBER: 2001:141740 BIOSIS  
DOCUMENT NUMBER: PREV200100141740  
TITLE: Diagnostic potentialities of enzyme immunoassay system for  
evaluation of the spectrum of antibodies to hepatitis C  
structural and nonstructural antigens.  
AUTHOR(S): Pimenov, V. K.; Afanasyev, A. Yu.; Kolobov, A. A.; Zubov,  
S. V.; Dobrotina, N. A.; Novikov, V. V.  
SOURCE: Voprosy Virusologii, (November-December, 2000) No. 6, pp.  
44-47. print.  
CODEN: VVIRAT. ISSN: 0507-4088.  
DOCUMENT TYPE: Article  
LANGUAGE: Russian  
ENTRY DATE: Entered STN: 21 Mar 2001  
Last Updated on STN: 15 Feb 2002

AB A new enzyme immunoassay EIA-HCV-Spectr test system constructed on the base of recombinant proteins and synthetic peptides allows separate detection of antibodies to E1/E2, core, NS3, NS4, and NS5 antigens of hepatitis C virus (HCV). The system is highly specific and more sensitive than the test systems used in screening studies, which allows its use as a final test for antiHCV antibodies. Antibodies to various HCV antigens were analyzed using this test system in patients with acute and chronic hepatitis C and asymptomatic donors with antiHCV. In acute hepatitis C during the first-second week after clinical manifestation, antibodies to nonstructural virus proteins are detected 3-4 times less often than in chronic hepatitis C. Acute hepatitis C is characterized by the presence of antibodies only to core antigen (68%). In chronic condition combinations of antibodies to structural and nonstructural HCV antigens predominate: core+NS4, core+NS3+NS4, core+NS3+NS5, core+NS4+NS5, and core+NS3+NS4+NS5. In asymptomatic donors with antiHCV and in patients with chronic hepatitis C the spectra of antibodies were similar in 45.7% cases.

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1648BQL

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	4	APR 04	STN AnaVist \$500 visualization usage credit offered
NEWS	5	MAY 10	CA/Capplus enhanced with 1900-1906 U.S. patent records
NEWS	6	MAY 11	KOREAPAT updates resume
NEWS	7	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS	8	MAY 30	IPC 8 Rolled-up Core codes added to CA/Capplus and USPATFULL/USPAT2
NEWS	9	MAY 30	The F-Term thesaurus is now available in CA/Capplus
NEWS	10	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS	11	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS	12	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS	13	JUL 11	CHEMSAFE reloaded and enhanced
NEWS	14	JUL 14	FSTA enhanced with Japanese patents
NEWS	15	JUL 19	Coverage of Research Disclosure reinstated in DWPI
NEWS	16	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	17	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	18	AUG 30	CA(SM)/Capplus(SM) Austrian patent law changes
NEWS EXPRESS		JUNE 30	CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 08:23:56 ON 31 AUG 2006

=> file caplus biosis  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION



FULL ESTIMATED COST

0.21

0.21

FILE 'CAPLUS' ENTERED AT 08:24:12 ON 31 AUG 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 08:24:12 ON 31 AUG 2006  
Copyright (c) 2006 The Thomson Corporation

=> HCV (s) conjugat3  
75% OF LIMIT FOR TOTAL ANSWERS REACHED  
L1 9357874 3

=> solid (s) phase  
L2 222835 SOLID (S) PHASE

=> carrier (w) protein  
L3 14905 CARRIER (W) PROTEIN

=> L1 and L3  
L4 4345 L1 AND L3

=> combinantion  
L5 11 COMBINANTION

=> L4 and L2  
L6 85 L4 AND L2

=> core and L6  
L7 0 CORE AND L6

=> Core (w) antigen  
L8 4778 CORE (W) ANTIGEN

=> L8 and L6  
L9 0 L8 AND L6

=> L8 and L1  
L10 1207 L8 AND L1

=> sensitiz3  
SYSTEM LIMITS EXCEEDED - SEARCH ENDED  
The search profile you entered was too complex or gave too many  
answers. Simplify or subdivide the query and try again. If you have  
exceeded the answer limit, enter DELETE HISTORY at an arrow prompt  
(=>) to remove all previous answers sets and begin at L1. Use the  
SAVE command to store any important profiles or answer sets before  
using DELETE HISTORY.

=> D history

(FILE 'HOME' ENTERED AT 08:23:56 ON 31 AUG 2006)

FILE 'CAPLUS, BIOSIS' ENTERED AT 08:24:12 ON 31 AUG 2006

L1 9357874 3  
L2 222835 SOLID (S) PHASE  
L3 14905 CARRIER (W) PROTEIN  
L4 4345 L1 AND L3  
L5 11 COMBINANTION  
L6 85 L4 AND L2  
L7 0 CORE AND L6  
L8 4778 CORE (W) ANTIGEN

L9 0 L8 AND L6  
L10 1207 L8 AND L1

=> NS3 and L10  
L11 59 NS3 AND L10

=> NS5 and L11  
L12 33 NS5 AND L11

=> conjugated and L12  
L13 0 CONJUGATED AND L12

=> synthetic and L12  
L14 5 SYNTHETIC AND L12

=> D L14 IBIB ABS 1-5

L14 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:287791 CAPLUS

DOCUMENT NUMBER: 140:320023

TITLE: DNA vaccine comprising plasmids encoding core-E1-E2,  
NS3-NS4 and NS5 genes for enhancing  
protective immunity to hepatitis C virus

INVENTOR(S): Sung, Young Chul; Youn, Jin-Won; Yang, Se-Hwan; Park,  
Su-Hyung; Lee, Chang Geun

PATENT ASSIGNEE(S): Genexine Inc., S. Korea; Postech Foundation; Dong-A  
Pharm. Co., Ltd.; Daewoong Co., Ltd.; Posco

SOURCE: PCT Int. Appl., 165 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004028563	A1	20040408	WO 2003-KR1951	20030924
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
KR 2004027247	A	20040401	KR 2002-68496	20021106
AU 2003263653	A1	20040419	AU 2003-263653	20030924
US 2005287117	A1	20051229	US 2005-528644	20050318
PRIORITY APPLN. INFO.:			KR 2002-58712	A 20020927
			KR 2002-68496	A 20021106
			WO 2003-KR1951	W 20030924

AB The present invention relates to a vaccine enhancing the protective immunity to Hepatitis C virus using plasmid DNA recombinant adenovirus, more particularly to a vaccine consisting of  $\Delta$  core-E1-E2 expressing DNA vaccine, nonstructural protein NS3 and NS4 expressing DNA vaccine, nonstructural protein NS5 expressing DNA vaccine and recombinant adenovirus vaccine, and method for administration of the vaccine by priming with the DNA vaccines described above and boosting with the recombinant adenovirus vaccine thereby enhancing the protective immunity to Hepatitis C virus.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:633162 CAPLUS  
 DOCUMENT NUMBER: 139:178676  
 TITLE: Methods for the simultaneous detection of hcv antigens and hcv antibodies  
 INVENTOR(S): Shah, Dinesh O.; Dawson, George J.; Muerhoff, A. Scott; Jiang, Lily; Gutierrez, Robin A.; Leary, Thomas P.; Desai, Suresh; Stewart, James L.  
 PATENT ASSIGNEE(S): Abbott Laboratories, USA  
 SOURCE: U.S. Pat. Appl. Publ., 63 pp., Cont.-in-part of U.S. Ser. No. 891,983.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003152948	A1	20030814	US 2002-173480	20020617
US 6727092	B2	20040427		
US 2003108858	A1	20030612	US 2001-891983	20010626
CA 2450710	AA	20030109	CA 2002-2450710	20020624
WO 2003002749	A2	20030109	WO 2002-US19958	20020624
WO 2003002749	A3	20030710		
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1412538	A2	20040428	EP 2002-746647	20020624
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2005518186	T2	20050623	JP 2003-509110	20020624
US 2004185436	A1	20040923	US 2004-753910	20040107
US 6855809	B2	20050215		
PRIORITY APPLN. INFO.:			US 2001-891983	A2 20010626
			US 2002-173480	A 20020617
			WO 2002-US19958	W 20020624

AB The subject invention relates to methods for the simultaneous detection of Hepatitis C Virus (HCV) antigens as well as antibodies produced in response to HCV antigens. Furthermore, the subject invention allows one to detect antigens in the early, acute stage of infection, even prior to the development of antibodies, thereby allowing for early detection of infected blood and blood products, thus improving the safety of the blood supply. The method allows the detection of the antigen or the antibody, or both, in a single assay. Antigens are detected with immobilized antibodies and antibodies are detected with immobilized antigens. After incubating the immobilized agents with a test sample, they are then incubated with labeled antibodies. Bound antigen is detected with an antibody to the antigen. Bound antibody is detected with a mouse monoclonal antibody to a human antibody, typically IgG.

L14 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:124651 CAPLUS  
 DOCUMENT NUMBER: 135:209508  
 TITLE: Diagnostic potential of an enzyme immunoassay system for evaluation of the spectrum of antibodies to hepatitis C structural and nonstructural antigens  
 AUTHOR(S): Pimenov, V. K.; Afanas'ev, A. Yu.; Kolobov, A. A.; Zubov, S. V.; Dobrotina, N. A.; Novikov, V. V.  
 CORPORATE SOURCE: Nizhegorod. Gos. Univ. im. N. I. Lobachevskogo, Nizhniy Novgorod, Russia

SOURCE: Voprosy Virusologii (2000), 45(6), 44-47  
 CODEN: VVIRAT; ISSN: 0507-4088  
 PUBLISHER: Meditsina  
 DOCUMENT TYPE: Journal  
 LANGUAGE: Russian

AB A new enzyme immunoassay EIA-HCV-Spectra test system constructed on the base of recombinant proteins and synthetic peptides allows sep. detection of antibodies to E1/E2, core, NS3, NS4, and NS5 antigens of hepatitis C virus (HCV). The system is highly specific and more sensitive than the test systems used in screening studies, which allows its use as a final test for antiHCV antibodies. Antibodies to various HCV antigens were analyzed using this test system in patients with acute and chronic hepatitis C and asymptomatic donors with antiHCV. In acute hepatitis C during the first-second week after clin. attis C and asymptomatic donors with antiHCV. In acute hepatitis C during the first and second week after clin. manifestation, antibodies to nonstructural virus proteins are detected 3-4 times less often than in chronic hepatitis C. Acute hepatitis C is characterized by the presence of antibodies only to core antigen (66%). In chronic condition combinations of antibodies to structural and nonstructural HCV antigens predominate: core + NS4, core + NS3 + NS4, core + NS3 + NS4 + NS5, core + NS4 + NS5, and core + NS3 + NS4 + NS5. In asymptomatic donors with antiHCV and in patients with chronic hepatitis C the spectra of antibodies were similar in 45.7% cases.

L14 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:54036 CAPLUS  
 DOCUMENT NUMBER: 126:73782  
 TITLE: Unprocessed core-envelope fusion protein and nonstructural protein for the diagnosis of and vaccination against hepatitis C virus  
 INVENTOR(S): Liao, Jaw-Ching; Wang, Cheng-Nan  
 PATENT ASSIGNEE(S): Bionova Corporation, USA; Liao, Jaw-Ching; Wang, Cheng-Nan  
 SOURCE: PCT Int. Appl., 73 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9637606	A1	19961128	WO 1996-US7378	19960522
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
ZA 9604094	A	19961203	ZA 1996-4094	19960522
AU 9659243	A1	19961211	AU 1996-59243	19960522
PRIORITY APPLN. INFO.:			US 1995-447276	A 19950522
			WO 1996-US7378	W 19960522

AB The unprocessed core protein region initially translated from the genome of hepatitis C virus (HCV) contains epitopic configurations that are not retained in the processed proteins. In particular, the core protein loses an epitopic configuration upon processing at the cleavage site between the genomic region (e.g., gene) encoding the core protein and the genomic region encoding the adjacent envelope region. The unprocessed epitopic configuration of the core region provides an improved ability to detect the presence of HCV, or antibodies to HCV, in a sample, including an

unpurified sample or a sample of very small volume (which can be particularly helpful when testing a sample from an infant or other person having very little blood (or other suitable material) available for testing). Combining the unprocessed core region with a nonstructural protein (such as an NS5 or an NS3-NS4 fusion) results in a synergistic effect that greatly enhances the already improved sensitivity and specificity provided by the unprocessed core region. The unprocessed epitopic configuration of the core region also provides an improved ability to induce an immune response upon administration of the core region into an animal. Recombinant methods are described for the preparation of a cloned DNA mol. (EN-80-2) derived from the HCV core and envelope regions and for a clone (EN-80-1) encoding the NS5 nonstructural protein.

L14 ANSWER 5 OF 5 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
ACCESSION NUMBER: 2001:141740 BIOSIS  
DOCUMENT NUMBER: PREV200100141740  
TITLE: Diagnostic potentialities of enzyme immunoassay system for  
evaluation of the spectrum of antibodies to hepatitis C  
structural and nonstructural antigens.  
AUTHOR(S): Pimenov, V. K.; Afanasyev, A. Yu.; Kolobov, A. A.; Zubov,  
S. V.; Dobrotina, N. A.; Novikov, V. V.  
SOURCE: Voprosy Virusologii, (November-December, 2000) No. 6, pp.  
44-47. print.  
CODEN: VVIRAT. ISSN: 0507-4088.  
DOCUMENT TYPE: Article  
LANGUAGE: Russian  
ENTRY DATE: Entered STN: 21 Mar 2001  
Last Updated on STN: 15 Feb 2002

AB A new enzyme immunoassay EIA-HCV-Spectr test system constructed on the base of recombinant proteins and synthetic peptides allows separate detection of antibodies to E1/E2, core, NS3, NS4, and NS5 antigens of hepatitis C virus (HCV). The system is highly specific and more sensitive than the test systems used in screening studies, which allows its use as a final test for antiHCV antibodies. Antibodies to various HCV antigens were analyzed using this test system in patients with acute and chronic hepatitis C and asymptomatic donors with antiHCV. In acute hepatitis C during the first-second week after clinical manifestation, antibodies to nonstructural virus proteins are detected 3-4 times less often than in chronic hepatitis C. Acute hepatitis C is characterized by the presence of antibodies only to core antigen (68%). In chronic condition combinations of antibodies to structural and nonstructural HCV antigens predominate: core+NS4, core+NS3+NS4, core+NS3+NS5, core+NS4+NS5, and core+NS3+NS4+NS5. In asymptomatic donors with antiHCV and in patients with chronic hepatitis C the spectra of antibodies were similar in 45.7% cases.